Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Observational

Strategic Targeting for Optimal Prevention of Cancer

NCT03897374 · tracked via the Priya Life Science USA tracker
Sponsor
ClinLogic LLC
Phase
Observational
Started
2025-03-26
Last updated
2026-03-19

Condition(s) studied

Early Detection of Cancer

Investigational drug(s) / intervention(s)

Genetic Testing

Genetic Testing: Buccal swab

Study summary

The primary goal of the study is to record data over the observation period to evaluate the clinical benefit of using hereditary cancer genomic diagnostics to assess overall hereditary genetic cancer risk profile and to help guide physicians to pursue preventative measures, which may lead to early detection and treatment of the condition.

Eligibility

Sex
ALL
Min age
65 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Study subjects may be included in the Clinical Trial if they meet all of the following inclusion criteria: * individuals, ages 65 years or older; * must have met medical necessity for hereditary cancer genomic testing and allowed the physician to test based on medical necessity; * hereditary cancer diagnostic test was ordered by a physician related to individual subject care considerations. * study subject has or had cancer * study subject has at least one family member with cirrent or past cancer Exclusion Criteria: * Study subjects will be excluded from the study if any of the following criteria apply: • study subject is currently hospitalized or incarcerated; * study subject is unable to provide an accurate history due to mental incapacity * study subject is currently abusing illicit and/or prescription drugs;

Primary outcome measure(s)

  • Genomic cancer screen — 120 Days
    A study subject is known to have personal and/or family history of cancer known to be influenced by genetic variation.
  • Genomic cancer screen — 120 Days
    A genotype known to be a predisposition for cancer.

Trial sites (1)

FacilityCityRegionStatus
Sunbeam Clinical Prosper Texas Recruiting

More ClinLogic LLC trials in the USA

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03897374 on ClinicalTrials.gov ↗ ← All trials in the USA